Date:12/5/2012

ns, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the anticipated benefits from the appointment of Mr. Mir as CFO, and the likelihood that it will lead to successful capital raising efforts; the development and implementation of a sustainable fiscal road map that can increase shareholder value by supporting continued growth, particularly in the marketing and sales area; our belief that our 2012 commercialization plan was integral to the record sales in the third quarter; that stakeholders in PBI will understand how fortunate they are that Mr. Mir has joined PBI as CFO; and that PCT is a powerful, enabling, and game-changing technology platform.  These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's product lines because scientists may not perceive the advantages of these products over other sample preparation methods; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital sooner than anticipated. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the
'/>"/>

SOURCE Pressure BioSciences, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
2. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
3. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
4. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
5. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
6. Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
7. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
8. Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
9. CTI Appoints Monique Greer, Senior Vice President, Corporate Communications and Investor Relations
10. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
11. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee